0
Pulmonary Vascular Disease: PAH |

Expert Consensus on the Prescribing Practice and Management of Adverse Events Associated With the Treatment of Patients Taking Macitentan for PAH: A Delphi Consensus Study

Franck Rahaghi, MD; Hassan Alnuaimat, MD; Rana Awdish, MD; Vijay Balasubramanian, MD; Robert Bourge, MD; Charles Burger, MD; John Butler, MD; C. Gregory Cauthen, MD; Murali Chakinala, MD; Bennett deBoisblanc, MD; Michael Eggert, MD; Peter Engel, MD; Jeremy Feldman, MD; J. Wesley McConnell, MD; Myung Park, MD; Jeffrey Sager, MD; Namita Sood, MD; Harold Palevsky, MD
Author and Funding Information

Cleveland Clinic, Weston, FL


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):1148A. doi:10.1016/j.chest.2016.08.1258
Text Size: A A A
Published online

Extract

SESSION TITLE: PAH

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Sunday, October 23, 2016 at 01:30 PM - 03:00 PM

PURPOSE: Pulmonary arterial hypertension (PAH) is a rare disease characterized by elevated pulmonary vascular resistance. Macitentan is an endothelin receptor antagonist indicated for the long-term treatment of PAH. This study presents consensus recommendations for managing macitentan and associated adverse events in PAH patients.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543